(Q39019344)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24586107%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

title

Protective role of humanin on bortezomib-induced bone growth impairment in anticancer treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24586107%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24586107%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Staffan Eksborg

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24586107%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Per Kogner

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24586107%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Lars Sävendahl

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24586107%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author name string

Emma Eriksson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24586107%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Lova Segerström Perup

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24586107%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

John I Johnsen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24586107%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

language of work or name

English

0 references

publication date

1 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24586107%20AND%20SRC:MED&resulttype=core&format=json

Journal of the National Cancer Institute

9 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24586107%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24586107%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24586107%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

djt459

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24586107%20AND%20SRC:MED&resulttype=core&format=json

Chronic health conditions in adult survivors of childhood cancer

9 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Long-term Complications Following Childhood and Adolescent Cancer: Foundations for Providing Risk-based Health Care for Survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Outcomes for children and adolescents with cancer: challenges for the twenty-first century

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Endochondral ossification: how cartilage is converted into bone in the developing skeleton.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Growth after radiotherapy and chemotherapy in children with leukemia or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Embryonal neural tumours and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Proteasome inhibition as a novel therapeutic target in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Lessons from the discovery of the ubiquitin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Bortezomib for the treatment of mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

The proteasome: a suitable antineoplastic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Bortezomib reverses a post-translational mechanism of tumorigenesis for patched1 haploinsufficiency in medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Inhibition of the proteasomal function in chondrocytes down-regulates growth plate chondrogenesis and longitudinal bone growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Proteasome inhibition therapies in childhood cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

S14G-Humanin ameliorates Abeta25-35-induced behavioral deficits by reducing neuroinflammatory responses and apoptosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Opposing roles of insulin-like growth factor binding protein 3 and humanin in the regulation of testicular germ cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

The neurosurvival factor Humanin inhibits beta-cell apoptosis via signal transducer and activator of transcription 3 activation and delays and ameliorates diabetes in nonobese diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Humanin improves impaired metabolic activity and prolongs survival of serum-deprived human lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor alpha/WSX-1/gp130

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Humanin: a novel central regulator of peripheral insulin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Humanin is a novel neuroprotective agent against stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Humanin preserves endothelial function and prevents atherosclerotic plaque progression in hypercholesterolemic ApoE deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Humanin peptide suppresses apoptosis by interfering with Bax activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Humanin binds and nullifies Bid activity by blocking its activation of Bax and Bak

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Cytoprotective peptide humanin binds and inhibits proapoptotic Bcl-2/Bax family protein BimEL

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Isolation of bone cell clones with differences in growth, hormone responses, and extracellular matrix production

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Chondrocyte differentiation in a rat mesenchymal cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Interleukin-1beta and TNF-alpha act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Starvation, detoxification, and multidrug resistance in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Dose translation from animal to human studies revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Of mice and men. When it comes to studying ageing and the means to slow it down, mice are not just small humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

Development of the proteasome inhibitor Velcade (Bortezomib).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT459

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJT459

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24586107%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference